Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead signs hepatitis C pact to cut drug cost for poor
September 15, 2014 at 09:04 AM EDT
[Reuters] – * Gilead plans to sell Sovaldi in India for $300 a month (Adds detail, background) Approximately 150 million people in the world live with chronic hepatitis C infection, most of them . . . → Read More: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead signs hepatitis C pact to cut drug cost for poor Similar Articles: Stock Update (NASDAQ:GILD): UK cost body backs pricey Gilead hepatitis pill for some patients Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – England agrees funding for Gilead hepatitis C drug Company Update (NASDAQ:GILD): Texas Medicaid holds off on proposed limits for Gilead hepatitis drug